Halofenate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563668

CAS#: 26718-25-2

Description: Halofenate is a selective peroxisome proliferator-activated receptor gamma (PPAR-gamma) modulator with antilipidemic activity.


Chemical Structure

img
Halofenate
CAS# 26718-25-2

Theoretical Analysis

MedKoo Cat#: 563668
Name: Halofenate
CAS#: 26718-25-2
Chemical Formula: C19H17ClF3NO4
Exact Mass: 415.0798
Molecular Weight: 415.79
Elemental Analysis: C, 54.89; H, 4.12; Cl, 8.53; F, 13.71; N, 3.37; O, 15.39

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Halofenate; MK-185; MK 185; MK185;

IUPAC/Chemical Name: 2-Acetamidoethyl 2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate

InChi Key: BJBCSGQLZQGGIQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)

SMILES Code: O=C(OCCNC(C)=O)C(C1=CC=C(Cl)C=C1)OC2=CC=CC(C(F)(F)F)=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 415.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gregoire FM, Zhang F, Clarke HJ, Gustafson TA, Sears DD, Favelyukis S, Lenhard J, Rentzeperis D, Clemens LE, Mu Y, Lavan BE. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88. doi: 10.1210/me.2008-0473. Epub 2009 Apr 23. PubMed PMID: 19389808; PubMed Central PMCID: PMC5419173.

2: Smith AG, Beaumont KA, Smit DJ, Thurber AE, Cook AL, Boyle GM, Parsons PG, Sturm RA, Muscat GE. PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells. Int J Biochem Cell Biol. 2009 Apr;41(4):844-52. doi: 10.1016/j.biocel.2008.08.037. Epub 2008 Sep 6. PubMed PMID: 18822385.

3: Zhang F, Lavan BE, Gregoire FM. Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects. PPAR Res. 2007;2007:32696. PubMed PMID: 17389769; PubMed Central PMCID: PMC1783742.

4: Allen T, Zhang F, Moodie SA, Clemens LE, Smith A, Gregoire F, Bell A, Muscat GE, Gustafson TA. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes. 2006 Sep;55(9):2523-33. PubMed PMID: 16936200.

5: Madhosingh C, Orr W. Halofenate and clofibrate inhibition of pyruvate dehydrogenase from Fusarium culmorum. J Environ Sci Health B. 1985 Apr;20(2):201-14. PubMed PMID: 3998411.

6: Gershbein LL. Effect of phenoxy acids on rat liver regeneration. Res Commun Chem Pathol Pharmacol. 1984 Feb;43(2):325-34. PubMed PMID: 6709967.

7: Kohl EA, Magner JA, Persellin ST, Vaughan GM, Kudzma DJ, Friedberg SJ. Improved control of non-insulin-dependent diabetes mellitus by combined halofenate and chlorpropamide therapy. Diabetes Care. 1984 Jan-Feb;7(1):19-24. PubMed PMID: 6368149.

8: Wood AJ, Feely J. Pharmacokinetic drug interactions with propranolol. Clin Pharmacokinet. 1983 May-Jun;8(3):253-62. Review. PubMed PMID: 6342901.

9: Colman RW. The role of platelets in the genesis of ischemia. Ann N Y Acad Sci. 1982;382:190-203. PubMed PMID: 6282171.

10: Beynen AC, Geelen MJ. Short-term inhibition of fatty acid biosynthesis in isolated hepatocytes by mono-aromatic compounds. Toxicology. 1982;24(3-4):183-97. Review. PubMed PMID: 6152823.

11: Wautier JL, Caen JP. Pharmacology of platelet-suppressive agents. Semin Thromb Hemost. 1979 Spring;5(4):293-315. Review. PubMed PMID: 386519.

12: Favis GR, Colman RW. The action of halofenate on platelet shape change and prostaglandin synthesis. J Lab Clin Med. 1978 Jul;92(1):45-52. PubMed PMID: 659964.

13: Huzoor-Akbar, Ardlie NG. Investigation of the role of arachidonic acid in platelet function and mechanisms for suppression of prostaglandin biosynthesis. Br J Haematol. 1978 May;39(1):71-81. PubMed PMID: 666979.

14: Yü TF, Dorph DJ, Smith H. Hyperlipidemia in primary gout. Semin Arthritis Rheum. 1978 May;7(4):233-44. Review. PubMed PMID: 347582.

15: Feldman EB, Gluck FB, Carter AC. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia. J Clin Pharmacol. 1978 May-Jun;18(5-6):241-8. PubMed PMID: 346616.

16: Colman RW. Platelet function in hyperbetalipoproteinemia. Thromb Haemost. 1978 Apr 30;39(2):284-93. PubMed PMID: 580982.

17: Kuntzen O, Hehl FJ, Walter E, Zimmermann R. [Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)]. Arzneimittelforschung. 1978;28(12):2349-52. German. PubMed PMID: 227420.

18: Colman RW. Platelet function in thrombosis and atherosclerosis. Adv Exp Med Biol. 1978;104:421-36. PubMed PMID: 213955.

19: Huzoor-Akbar, Ardlie NG. The effect of halofenate--free acid on aggregation--the release reaction, coagulant activity, and lipid metabolism of human platelets. Thromb Haemost. 1977 Oct 31;38(3):612-9. PubMed PMID: 579507.

20: Karch FE, Wardell WM, Dambly M, Gringeri A. Effect of halofenate on the serum binding of phenytoin. Br J Clin Pharmacol. 1977 Oct;4(5):625-6. PubMed PMID: 911611; PubMed Central PMCID: PMC1429162.